As the global cannabis industry continues to absorb what a potential US rescheduling of cannabis would mean for its future, VDX.tv’s Director of Client Partnerships for CBD, Lauren White, explained to Business of Cannabis why this could ‘enable cannabis companies to step out of the shadows and establish themselves in the mainstream market’.
Emerging Avenues in Advertising for Cannabis
The US Department of Health and Human Services has recommended reclassifying marijuana as a lower-risk drug, which would in turn ease restrictions. While this new Schedule III recommendation holds a myriad of implications including banking and tax codes, a standout beneficiary will be the domain of advertising. With barriers lifting, advertising platforms and strategies for cannabis (and CBD) enterprises are set to revolutionise.
As federal restrictions around this category ease, the media world, once apprehensive about cannabis advertising, should see a renaissance. Previously off-limits platforms will likely open up, enabling cannabis companies to step out of the shadows and establish themselves in the mainstream market.
A few reasons why it will be crucial for CBD and cannabis brands to work with reputable adtech partners that are versed in this industry:
Harnessing the Power of Streaming: With audiences transitioning from linear to streaming TV, it’s becoming essential for brands to meet consumers where they are. These cannabis companies need to understand that modern viewers, especially the younger demographics, never had a “cord to cut” in the first place! Being present on platforms like connected TV (CTV), over the top (OTT) and online video isn’t just about being trendy; it’s about being where your consumers are and educating them about these products.
Innovative Measurement and Integration Tools: In the modern age, data isn’t just power; it’s insight, foresight, and strategy all rolled into one. Brands that leverage comprehensive measurement tools stand to gain a deeper understanding of their campaigns’ impact. For instance, being able to measure sales lift directly from a campaign can offer invaluable insights. Strategic integrations related to measurement and shoppability of ads further amplify the power of ongoing campaign optimization and immediate return. This not only streamlines the customer journey but also fosters immediate conversion, enhancing overall consideration and purchase intent.
Staying Compliant: The world of cannabis, given its tumultuous history, is rife with legal intricacies. For these cannabis companies navigating these complexities can be daunting. It’s crucial to prioritize compliance and stay abreast of the latest guidelines, especially from agencies like the FDA. A slip-up here can damage brand reputation. This is where being in tune with the legal side is invaluable. It’s important that advertising partners understand all sides of the industry to ensure brand safety and best practices.
Building Bridges with Publishers: In an evolving landscape, not all players are equal. Building relationships with forward-thinking publishers can be the differentiating factor in a brand’s advertising success. Publishers who understand and are excited about the cannabis industry can offer avenues and insights that others can’t. That’s where a managed service partner can help open doors that others may not be able to. As cannabis brands start to embrace advertising, its critical to find trusted partners who reach the right audience, in the right way, with the right message.
In essence, the cannabis industry stands at the cusp of an advertising revolution. As the barriers slowly fall away (or show promising momentum that direction), brands have an unprecedented opportunity to redefine their public persona and bring in new customers.
Ben Stevens
Ben is the editor of Business of Cannabis. Since 2021, he has researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.
A comprehensive, thoughtfully curated overview of the stories defining today's cannabis sector — breaking news, investigative features, expert commentary, and context-rich analysis to help you navigate events with clarity and confidence.
Home / DHHS Recommendation Could See New Era in Cannabis Advertising
DHHS Recommendation Could See New Era in Cannabis Advertising
As the global cannabis industry continues to absorb what a potential US rescheduling of cannabis would mean for its future, VDX.tv’s Director of Client Partnerships for CBD, Lauren White, explained to Business of Cannabis why this could ‘enable cannabis companies to step out of the shadows and establish themselves in the mainstream market’.
Emerging Avenues in Advertising for Cannabis
The US Department of Health and Human Services has recommended reclassifying marijuana as a lower-risk drug, which would in turn ease restrictions. While this new Schedule III recommendation holds a myriad of implications including banking and tax codes, a standout beneficiary will be the domain of advertising. With barriers lifting, advertising platforms and strategies for cannabis (and CBD) enterprises are set to revolutionise.
As federal restrictions around this category ease, the media world, once apprehensive about cannabis advertising, should see a renaissance. Previously off-limits platforms will likely open up, enabling cannabis companies to step out of the shadows and establish themselves in the mainstream market.
A few reasons why it will be crucial for CBD and cannabis brands to work with reputable adtech partners that are versed in this industry:
In essence, the cannabis industry stands at the cusp of an advertising revolution. As the barriers slowly fall away (or show promising momentum that direction), brands have an unprecedented opportunity to redefine their public persona and bring in new customers.
Ben Stevens
Other featured articles
DEA Rescheduling Hearing Closes as States’ Own Witness Concedes Regulation Reduces Crime
By
US Rescheduling Hearing Nears End as Opposition’s Own Witness Acknowledges Cannabis Fits Schedule III Standard
By
Germany Bans Cannabis Flowers from GKV and Mandates Six-Month Trial for Extracts
By
Why Medical Companies Win Rescheduling, Whatever Happens to Adult-Use
By
‘No Right to GMP Washing’: German State Challenges Cannabis Flower Import Compliance
By
Other featured Opinion articles
Why Medical Companies Win Rescheduling, Whatever Happens to Adult-Use
By
Who Really Benefits from Britain’s Medical Cannabis System?
By
Is the US Hemp Ban Punishing the Wrong People?
By
Cannabis at an Inflexion Point: A Structural Repricing Ahead
By
Europe’s Medical Cannabis Market Has Grown Up, Now Its Supply Chain Needs To
By
Share Article
The Briefing / Newsletter
Insights
you don't want
to miss.
A comprehensive, thoughtfully curated overview of the stories defining today's cannabis sector — breaking news, investigative features, expert commentary, and context-rich analysis to help you navigate events with clarity and confidence.
Related news
DEA Rescheduling Hearing Closes as States’ Own Witness Concedes Regulation Reduces Crime
By
US Rescheduling Hearing Nears End as Opposition’s Own Witness Acknowledges Cannabis Fits Schedule III Standard
By
Germany Bans Cannabis Flowers from GKV and Mandates Six-Month Trial for Extracts
By
Why Medical Companies Win Rescheduling, Whatever Happens to Adult-Use
By
‘No Right to GMP Washing’: German State Challenges Cannabis Flower Import Compliance
By
EU Medical Cannabis Faces Its Most Consequential Regulatory Overhaul
By
France Breaks Medical Cannabis Deadlock as Reimbursement Decree Filed for Legal Review
By
DEA Opens Rescheduling Hearing With Science-Based Support for Its Own Rule
By
Who Really Benefits from Britain’s Medical Cannabis System?
By